Octreotide

SandostatinGI/Bone/Other

Evidence grade

AFDA-approved Rx (labeled use)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeEndocrine / GI

MechanismSomatostatin analog suppressing GH, insulin, glucagon and multiple GI hormones

EffectsSuppresses the GH axis rather than stimulating it — the mirror image of the secretagogue peptides

DosingImmediate release 50-100 mcg SC two to three times daily; LAR 20 mg IM every 4 weeks

Bottom lineStrongest data when used for its labeled indication under clinician guidance.

Batches on filenone

No tested batches on file.

Read with10

Tesamorelin Somatropin Sermorelin CJC-1295 (no DAC)Ipamorelin GHRP-2 GHRP-6 Desmopressin (DDAVP)Teriparatide (Forteo)Abaloparatide (Tymlos)

Cautions & interactions

Gallstones with prolonged use; glucose dysregulation in both directions; bradycardia; GI upset

Alters insulin and oral diabetes medication requirements; affects ciclosporin and bromocriptine levels; monitor thyroid function.

CV 2 of 5 — Can cause bradycardia and conduction changes; monitor in patients with existing cardiac disease.